Investor Relations Home

Corporate Profile

NeuroDerm is a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system disorders, through proprietary formulations based on existing drugs that are intended to make a significant difference in patients' lives. NeuroDerm currently has four product candidates in development designed to treat moderate to severe Parkinson’s disease. The company designed its product candidates to overcome major deficiencies of current treatments and achieve enhanced clinical efficacy through continuous, controlled administration, primarily subcutaneously or transdermally.

Title
Download Documentation NeuroDerm January 2017 Corporate Presentation

Recent News

More >>
DateTitle 
01/03/17NeuroDerm CEO to Present at the 35th Annual J.P. Morgan Healthcare Conference on January 12, 2017
REHOVOT, Israel, Jan. 03, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that CEO Oded S. Lieberman, PhD will present at the 35th Annual J.P. Morgan Healthcare Conference on Thursday, January 12 at 10:30 am PT / 1:30 pm ET in San Francisco.  Dr. Lieberman will give a corporate overview and discuss the company's flagship product candidates designed to treat moderate to sev... 
Printer Friendly Version
12/22/16NeuroDerm Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
REHOVOT, Israel, Dec. 22, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (NASDAQ:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced the closing of the offering of an additional 600,000 shares at a public offering price of $18.75 pursuant to the underwriters’ option to purchase additional shares in its recently completed public offering. All of the ordinary shares were issued and sold by NeuroDerm. The underwriters exercised in fu... 
Printer Friendly Version
12/22/16NeuroDerm Announces Completion of Patient Enrollment and Treatment in a Phase II Trial of ND0612H for Advanced Parkinson’s Disease
- First evaluation of clinical efficacy of ND0612H in advanced Parkinson's patients - REHOVOT, Israel, Dec. 22, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today announced that it completed patient enrollment and treatment in trial 006 of ND0612H, the company's continuously administered levodopa/carbidopa (LD/CD) solution. ND0612H, administered subcutaneously through a belt pump, is... 
Printer Friendly Version

Upcoming Events | Past Events

More >>
There are currently no events scheduled.